ES2644982T3 - Anticuerpos contra CD38 para el tratamiento del mieloma múltiple - Google Patents

Anticuerpos contra CD38 para el tratamiento del mieloma múltiple Download PDF

Info

Publication number
ES2644982T3
ES2644982T3 ES12178778.2T ES12178778T ES2644982T3 ES 2644982 T3 ES2644982 T3 ES 2644982T3 ES 12178778 T ES12178778 T ES 12178778T ES 2644982 T3 ES2644982 T3 ES 2644982T3
Authority
ES
Spain
Prior art keywords
antibody
seq
human
sequence
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
ES12178778.2T
Other languages
English (en)
Spanish (es)
Inventor
Yvo Graus
Paul Parren
Jan Van De Winkel
Michel De Weers
Judith Oprins
Martine Van Vugt
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Genmab AS
Original Assignee
Genmab AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab AS filed Critical Genmab AS
Application granted granted Critical
Publication of ES2644982T3 publication Critical patent/ES2644982T3/es
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
ES12178778.2T 2005-03-23 2006-03-23 Anticuerpos contra CD38 para el tratamiento del mieloma múltiple Expired - Lifetime ES2644982T3 (es)

Applications Claiming Priority (8)

Application Number Priority Date Filing Date Title
DKPA200500429 2005-03-23
DK200500429 2005-03-23
US66757905P 2005-04-01 2005-04-01
US667579P 2005-04-01
US69616305P 2005-07-01 2005-07-01
US696163P 2005-07-01
US72856105P 2005-10-20 2005-10-20
US728561P 2005-10-20

Publications (1)

Publication Number Publication Date
ES2644982T3 true ES2644982T3 (es) 2017-12-01

Family

ID=50644285

Family Applications (2)

Application Number Title Priority Date Filing Date
ES12178778.2T Expired - Lifetime ES2644982T3 (es) 2005-03-23 2006-03-23 Anticuerpos contra CD38 para el tratamiento del mieloma múltiple
ES06722861.9T Expired - Lifetime ES2606762T3 (es) 2005-03-23 2006-03-23 Anticuerpos contra CD38 para el tratamiento del mieloma múltiple

Family Applications After (1)

Application Number Title Priority Date Filing Date
ES06722861.9T Expired - Lifetime ES2606762T3 (es) 2005-03-23 2006-03-23 Anticuerpos contra CD38 para el tratamiento del mieloma múltiple

Country Status (12)

Country Link
KR (1) KR20140033240A (enExample)
BE (1) BE2017C062I2 (enExample)
DK (1) DK1866338T3 (enExample)
ES (2) ES2644982T3 (enExample)
HU (2) HUE030783T2 (enExample)
LT (2) LT2567976T (enExample)
NZ (2) NZ600059A (enExample)
PL (1) PL1866338T3 (enExample)
PT (2) PT2567976T (enExample)
RS (1) RS55442B1 (enExample)
SG (1) SG10201610317VA (enExample)
UA (2) UA98756C2 (enExample)

Also Published As

Publication number Publication date
ES2606762T3 (es) 2017-03-27
LT2567976T (lt) 2017-12-11
KR20140033240A (ko) 2014-03-17
NZ625944A (en) 2016-01-29
UA98756C2 (ru) 2012-06-25
RS55442B1 (sr) 2017-04-28
DK1866338T3 (da) 2017-01-02
HUE030783T2 (en) 2017-06-28
HUE034962T2 (en) 2018-03-28
BE2017C062I2 (enExample) 2025-12-03
LT1866338T (lt) 2017-01-25
SG10201610317VA (en) 2017-02-27
PL1866338T3 (pl) 2017-04-28
UA116520C2 (uk) 2018-04-10
PT1866338T (pt) 2016-12-14
PT2567976T (pt) 2017-10-19
NZ600059A (en) 2016-01-29

Similar Documents

Publication Publication Date Title
US20240132620A1 (en) Antibodies against cd38 for treatment of multiple myeloma
US20090076249A1 (en) Antibodies against CD38 for treatment of multiple myeloma
ES2644982T3 (es) Anticuerpos contra CD38 para el tratamiento del mieloma múltiple
HK1236545A1 (en) Antibodies against cd38 for treatment of multiple myeloma
HK1107826B (en) Antibodies against cd38 for treatment of multiple myeloma
HK1179979B (en) Antibodies against cd38 for treatment of multiple myeloma
HK1179979A (en) Antibodies against cd38 for treatment of multiple myeloma
HK1183047B (en) Antibodies against cd38 for treatment of multiple myeloma
HK1183047A (en) Antibodies against cd38 for treatment of multiple myeloma